ArticleDrug discovery today2011
The challenge of developing robust drugs to overcome resistance.
Article in Drug discovery today, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- miRNA-765 mediates multidrug resistance via targeting BATF2 in gastric cancer cells.FEBS open bio · 2020Observational
- Embryonic zebrafish xenograft assay of human cancer metastasis.F1000Research · 2018Article
- Fused-Ring Oxazolopyrrolopyridopyrimidine Systems with Gram-Negative Activity.Antibiotics (Basel, Switzerland) · 2017Article
- Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Effect of pH on anti-rotavirus activity by comestible juices and proanthocyanidins in a cell-free assay system.Food and environmental virology · 2012Article
- Combatting Drug-Resistant Bacteria with Gyrase and Topoisomerase IV Inhibitors: Patent Highlight.ACS medicinal chemistry letters · 2012Article
- Winning the arms race by improving drug discovery against mutating targets.ACS chemical biology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Drug resistance is problematic in microbial disease, viral disease and cancer. Understanding at the outset that resistance will impact the effectiveness of any new drug that is developed for these disease categories is imperative. In this Feature, we detail approaches that have been taken with selected drug targets to reduce the susceptibility of new drugs to resistance mechanisms. We will also define the concepts of robust drugs and resilient targets, and discuss how the design of robust drugs and the selection of resilient targets can lead to successful strategies for combating resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.